Showing results (301-310 of 335) with videos related to
Sort By:
Pageof 34
American Journal of Clinical Oncology|October 11, 2008
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium TrialY Yen, Dean W Lim, Vincent Chung, et al.European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignanciesD Mahadevan, E G Chiorean, W B Harris, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid TumorsDaniel D Von Hoff, Monica M Mita, Ramesh K Ramanathan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineDavendra P S Sohal, Pamela B Mangu, Alok A Khorana, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2007
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741Grace K Dy, James E Krook, Erin M Green, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal functionChris H Takimoto, Martin A Graham, Graham Lockwood, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupRamesh K Ramanathan, Merrill J Egorin, Chris H M Takimoto, et al.British Journal of Cancer|December 21, 2019
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinomaAna De Jesus-Acosta, Elizabeth A Sugar, Peter J O'Dwyer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerE G Chiorean, D D Von Hoff, M Reni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline UpdateDavendra P S Sohal, Erin B Kennedy, Alok Khorana, et al.Pageof 34